Obio Technology Shanghai Corp

Obio Technology Shanghai Corp EBIT per Employee

The EBIT per Employee of Obio Technology Shanghai Corp (688238.SS) as of Oct 30, 2026 is -359,598.45 CNY. In the previous year, EBIT per Employee was -495,144.47 CNY — a change of -27.38% (higher).

EBIT per Employee

-359,598.45CNY

YoY

-27.38%

Last updated:

EBIT per Employee of Obio Technology Shanghai Corp is 2025 -359,598.45 CNY. EBIT per Employee of Obio Technology Shanghai Corp was 2024 -495,144.47 CNY. It decreases by -27.38% higher compared to the previous year.

The Obio Technology Shanghai Corp EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-51,911.57 CNY
Jan 1, 2019
-64,027.71 CNY
Jan 1, 2021
79,327.14 CNY
Jan 1, 2022
23,795.42 CNY
Jan 1, 2023
-247,585.02 CNY
Jan 1, 2024
-495,144.47 CNY
Jan 1, 2025
-359,598.45 CNY
The Obio Technology Shanghai Corp EBIT per Employee history
YEAREBIT per EmployeeYoY
-359,598.45CNY-27.38%
-495,144.47CNY+99.99%
-247,585.02CNY-1,140.47%
23,795.42CNY-70.00%
79,327.14CNY-223.90%
-64,027.71CNY+23.34%
-51,911.57CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Obio Technology Shanghai Corp Stock analysis

What does Obio Technology Shanghai Corp do? Obio Technology Shanghai Corp Ltd provides biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO services. The company offers contract research organization (CRO) services including gene therapy vector development and gene function research for gene therapy basic research, as well as contract research and development production organization (CDMO) services for gene drug R&D, such as pharmaceutical research and clinical sample production. It serves European and American markets and the domestic market with its CRO and CDMO offerings. The firm generates revenue through CRO services like gene therapy vector development and gene function research, and CDMO services including pharmaceutical research and clinical sample production. Its primary clients are companies involved in gene therapy and gene drug development, focusing on the European and American markets and domestic segments. The company's services support the research and development phases of gene therapy and gene drug products. Obio Technology Shanghai Corp Ltd's business model centers on providing specialized research and production services for gene therapy and gene drug development. By offering both CRO and CDMO services, it addresses key needs in the gene therapy industry, particularly in vector development and clinical sample production, targeting pharmaceutical companies and research institutions in Europe, America, and China. Obio Technology Shanghai Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Obio Technology Shanghai Corp stock

EBIT per Employee of Obio Technology Shanghai Corp is -359,598.45 CNY in 2025.

EBIT per Employee of Obio Technology Shanghai Corp changed from -495,144.47 CNY to -359,598.45 CNY, representing a -27.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Obio Technology Shanghai Corp since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Obio Technology Shanghai Corp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Obio Technology Shanghai Corp

All Key Metrics — Obio Technology Shanghai Corp